Cleo Diagnostics Ltd (COV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cleo Diagnostics Ltd (COV) has a cash flow conversion efficiency ratio of -0.189x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$8.83 Million ≈ $6.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cleo Diagnostics Ltd (COV) total market value for the company's overall valuation and market capitalisation.
Cleo Diagnostics Ltd - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Cleo Diagnostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cleo Diagnostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cleo Diagnostics Ltd ranked by their cash flow conversion efficiency. See COV cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KWG Group Holdings Limited
F:KOU
|
0.049x |
|
Mitie Group PLC
LSE:MTO
|
0.288x |
|
TeraGo Inc.
TO:TGO
|
-0.032x |
|
Atico Mining Corporation
V:ATY
|
0.001x |
|
ES Ceramics Technology Bhd
KLSE:0100
|
0.022x |
|
Datron AG
XETRA:DAR
|
0.117x |
|
Poulaillon SA
PA:ALPOU
|
0.198x |
|
Mereo BioPharma Group plc
F:MAH0
|
-0.188x |
Annual Cash Flow Conversion Efficiency for Cleo Diagnostics Ltd (2023–2025)
The table below shows the annual cash flow conversion efficiency of Cleo Diagnostics Ltd from 2023 to 2025. View current stock price of Cleo Diagnostics Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.83 Million ≈ $4.13 Million |
AU$-2.90 Million ≈ $-2.05 Million |
-0.497x | -130.03% |
| 2024-06-30 | AU$9.39 Million ≈ $6.65 Million |
AU$-2.03 Million ≈ $-1.44 Million |
-0.216x | -129.79% |
| 2023-06-30 | AU$-943.41K ≈ $-667.52K |
AU$-684.47K ≈ $-484.31K |
0.726x | -- |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more